Diabetes Metab J.  2023 Mar;47(2):198-200. 10.4093/dmj.2023.0038.

Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease

• Jung HN
• Jung CH

• KMID: 2540516
• DOI: http://doi.org/10.4093/dmj.2023.0038

Reference

1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67:328–57.

2. Demirtas CO, Yilmaz Y. Metabolic-associated fatty liver disease: time to integrate ground-breaking new terminology to our clinical practice? Hepatol Forum. 2020; 1:79–81.

3. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020; 73:202–9.

4. Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality? Results from NHANES III. Front Med (Lausanne). 2021; 8:693507.

5. Kaya E, Yilmaz Y. Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease. Ther Adv Endocrinol Metab. 2022; 13:20420188221139650.

6. Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020; 40:3018–30.

7. Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020; 40:2082–9.

8. Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, et al. MAFLD and risk of CKD. Metabolism. 2021; 115:154433.

9. Hashimoto Y, Hamaguchi M, Okamura T, Nakanishi N, Obora A, Kojima T, et al. Metabolic associated fatty liver disease is a risk factor for chronic kidney disease. J Diabetes Investig. 2022; 13:308–16.

10. Jung CY, Koh HB, Park KH, Joo YS, Kim HW, Ahn SH, et al. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: a nationwide cohort study. Diabetes Metab. 2022; 48:101344.

11. Miao L, Yang L, Guo LS, Shi QQ, Zhou TF, Chen Y, et al. Metabolic dysfunction-associated fatty liver disease is associated with greater impairment of lung function than nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2022; 10:230–7.

12. Fukunaga S, Nakano D, Kawaguchi T, Eslam M, Ouchi A, Nagata T, et al. Non-obese MAFLD is associated with colorectal adenoma in health check examinees: a multicenter retrospective study. Int J Mol Sci. 2021; 22:5462.

13. Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022; 10:329–38.

14. Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021; 75:1284–91.

15. Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol. 2021; 19:2172–81.e6.

16. Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021; 19:2138–47.e10.

17. Guerreiro GT, Longo L, Fonseca MA, de Souza VE, Alvares-da-Silva MR. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD? Hepatol Int. 2021; 15:380–91.

18. Kim KS, Hong S, Ahn HY, Park CY. Metabolic dysfunction-associated fatty liver disease and mortality: a population-based cohort study. Diabetes Metab J. 2023; 47:220–31.

19. Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021; 385:1559–69.

20. Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020; 14:889–919.